Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 3054145, 10 pages
https://doi.org/10.1155/2017/3054145
Research Article

Effect of Huayu Tongluo Herbs on Reduction of Proteinuria via Inhibition of Wnt/β-Catenin Signaling Pathway in Diabetic Rats

1Hebei Medical University, Shijiazhuang, Hebei 050017, China
2Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200, China
3Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang, Hebei 050011, China

Correspondence should be addressed to Zhiqiang Chen

Received 19 January 2017; Accepted 30 April 2017; Published 1 June 2017

Academic Editor: Mariangela Rondanelli

Copyright © 2017 Lu Bai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. W. F. Keane and P. A. Lyle, “Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study,” American Journal of Kidney Diseases, vol. 41, supplement 1, no. 3, pp. S22–S25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. F. N. Pathoge and G. Wolf, “Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy,” Current Diabetes Reviews, vol. 4, no. 1, pp. 39–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. X. J. Long, S. Lin, X. Zhang et al., “Correlation between podocyte excretion and proteinuria in diabetic nephropathy patients,” Journal of Medical Colleges of PLA, vol. 25, no. 3, pp. 180–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Dai, D. B. Stolz, L. P. Kiss, S. P. Monga, L. B. Holzman, and Y. Liu, “Wnt/β-catenin signaling promotes podocyte dysfunction and albuminuria,” Journal of the American Society of Nephrology, vol. 20, no. 9, pp. 1997–2008, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. W. He, C. Dai, Y. Li, G. Zeng, S. P. Monga, and Y. Liu, “Wnt/beta-catenin signaling promotes renal interstitial fibrosis,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 765–776, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Tan, D. Zhou, L. Zhou, and Y. Liu, “Wnt/β-catenin signaling and kidney fibrosis,” Kidney International Supplements, vol. 4, no. 1, pp. 84–90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. L. Wu, C. Wei, Z. H. Jia, and Z. M. Zhu, “Discuss the pathogenesis of diabetic nephropathy from Luo disease theory,” Journal of Basic Chinese Medicine, vol. 13, no. 9, pp. 659-660, 2007. View at Google Scholar
  9. X. J. Hu, Y. Qin, T. Y. Liu, and X. Z. Niu, “Clinical study on correlation between TCM syndrome type and renal collateral stasis in diabetic nephropathy,” Liaoning Journal of Traditional Chinese Medicine, vol. 43, no. 1, pp. 91-92, 2016. View at Google Scholar
  10. J. Xu, E. W. Ma, L. Bai et al., “Verification of stasis- blocking- collaterals syndrome in rat model with diabetic nephropathy,” Chinese Journal of Integrated Traditional and Western Nephrology, vol. 15, no. 1, pp. 12–15, 2014. View at Google Scholar
  11. C. Cao, S. M. Hao, Z. S. Meng et al., “Effect of huayu tongluo traditional chinese medicine on metabolic parameters and slit membrane protein nephrin impression in diabetic nephropathy rats,” Chinese Journal of Integrated Traditional and Western Nephrology, vol. 17, no. 6, pp. 484–487, 2016. View at Google Scholar
  12. J. Fang, Z. Q. Chen, Q. Guo et al., “Regulatory effect of chinese drugs for stasis removing and collaterals dredging on the expressions of podocin and cd2ap in podocyte slit diaphragm of diabetic nephropathy rats,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 36, no. 7, pp. 835–841, 2016. View at Google Scholar
  13. Chen Q., Methodology for TCM Pharmacological Studies, People's Medical Publishing House, Beijing, China, 2nd edition, 2006.
  14. X. J. Hu, Q. Li, T. Li et al., “Study on correlation between syndromes of diabetic nephropathy and blood stasis syndrome in chinese medicine,” Shanxi Journal of Traditional Chinese Medicine, vol. 33, no. 11, pp. 1487-1488, 2012. View at Google Scholar
  15. X. Mou, A. W. Zhuang, G. L. Ma et al., “Cluster analysis of syndrome differentiation types of 237 cases of diabetic kidney disease in clinical stage,” Chinese Archives of Traditional Chinese Medicine, vol. 34, no. 2, pp. 332–335, 2016. View at Google Scholar
  16. L. P. Yang, P. Li, J. H. Du et al., “Canonical correlation analysis of TCM syndrome and laboratory parameters in 350 patients with diabetic nephropathy,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 25, no. 5, pp. 686–689, 2010. View at Google Scholar
  17. Q. Guo, Z. Q. Chen, J. Fang et al., “Clinical efficacy of Yiqi Yangyin xiaozheng Tongluo Fang on patients with stage IV diabetic nephropathy,” Journal of Beijing University of Traditional Chinese Medicine, vol. 39, no. 9, pp. 779–782, 2016. View at Google Scholar
  18. J. Xu, L. Bai, E. W. Ma et al., “Correlativity between blood measures related to blood stasis blocking collaterals and gene expression of angiotensin-converting enzyme of renal cortex in diabetic rats and effect of stasis removing and collaterals dredging,” Journal of Traditional Chinese Medicine, vol. 34, no. 5, pp. 597–603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Xu, E. W. Ma, L. Bai et al., “Effect of chinese herbs for stasis removing and collaterals dredging upon angiotensin-converting enzyme 2-angiotensin-(1-7)-mas axis in the renal cortex of diabetic nephropathy rats,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 34, no. 6, pp. 714–721, 2014. View at Google Scholar
  20. M. A. Naves, L. R. Requião-Moura, M. F. Soares, J. A. Silva-Júnior, G. Mastroianni-Kirsztajn, and V. P. C. Teixeira, “Podocyte Wnt/β-catenin pathway is activated by integrin-linked kinase in clinical and experimental focal segmental glomerulosclerosis,” Journal of Nephrology, vol. 25, no. 3, pp. 401–409, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Zhou, X. He, R. Cheng et al., “Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy,” Diabetologia, vol. 55, no. 1, pp. 255–266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Li and H. M. Siragy, “High glucose induces podocyte injury via enhanced (pro) renin receptor-Wnt-β-catenin-snail signaling pathway,” PLoS ONE, vol. 9, no. 2, Article ID e89233, 2014. View at Publisher · View at Google Scholar
  23. A. J. Huo, J. F. Ma, C. C. Li et al., “Effect of high glucose and lipopolysaccharide on expression of beta catenin in peritoneal mesothelial cells and fibrosis,” Chinese Journal of Nephrology, vol. 28, no. 2, pp. 255–266, 2012. View at Google Scholar
  24. T. Kawakami, S. Ren, and J. S. Duffield, “Wnt signalling in kidney diseases: dual roles in renal injury and repair,” Journal of Pathology, vol. 229, no. 2, pp. 221–231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Kato, A. Gruenwald, J. H. Suh et al., “Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival,” The Journal of Biological Chemistry, vol. 286, no. 29, pp. 26003–26015, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Surendran, S. P. McCaul, and T. C. Simon, “A role for Wnt-4 in renal fibrosis,” American Journal of Physiology - Renal Physiology, vol. 282, no. 3, pp. F431–F441, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Mesar, P. Kes, and N. B. Jukić, “A role of WNT in kidney development and function,” Acta medica Croatica, vol. 66, supplement 2, pp. 56–58, 2012. View at Google Scholar
  28. C. Jinxiao, Y. Hongwei, R. Dan-Ni et al., “LRP6 dimerization through its LDLR domain is required for robust canonical Wnt pathway activation,” Cellular Signalling, vol. 26, no. 5, pp. 1068–1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. B. T. MacDonald, K. Tamai, and X. He, “Wnt/β-catenin signaling: components, mechanisms, and diseases,” Developmental Cell, vol. 17, no. 1, pp. 9–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Wang, C. Dai, Y. Li, and Y. Liu, “Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria,” Kidney International, vol. 80, no. 11, pp. 1159–1169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Heikkilä, J. Juhila, M. Lassila et al., “β-Catenin mediates adriamycin-induced albuminuria and podocyte injury in adult mouse kidneys,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2437–2446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kuusela, H. Wang, A. A. Wasik et al., “Tankyrase inhibition aggravates kidney injury in the absence of CD2AP,” Cell Death and Disease, vol. 21, no. 7, Article ID e2302, 2016. View at Publisher · View at Google Scholar
  33. A. A. Eddy, “Overview of the cellular and molecular basis of kidney fibrosis,” Kidney International Supplements, vol. 4, no. 1, pp. 2–8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Ding and M. E. Choi, “Regulation of autophagy by TGF-β: emerging role in kidney fibrosis,” Seminars in Nephrology, vol. 34, no. 1, pp. 62–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Sureshbabu, S. A. Muhsin, M. E. Choi et al., “TGF-β signaling in the kidney: profibrotic and protective effects,” American Journal of Physiology - Renal Physiology, vol. 310, no. 7, pp. F596–F606, 2016. View at Publisher · View at Google Scholar
  36. G. E. Hannigan, C. Leung-Hagesteijn, L. Fitz-Gibbon et al., “Regulation of cell adhesion and anchorage-dependent growth by a new β1-integrin-linked protein kinase,” Nature, vol. 379, article 6560, pp. 91–96, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Li, J. Yang, C. Dai et al., “Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis,” Journal of Clinical Investigation, vol. 112, no. 4, pp. 503–516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Kretzler, V. P. Teixeira, P. G. Unschuld et al., “Integrin-linked kinase as a candidate downstream effector in proteinuria,” The FASEB Journal, vol. 15, no. 10, pp. 1843–1845, 2001. View at Publisher · View at Google Scholar
  39. V. De Paulo Castro Teixeira, S. M. Blattner, M. Li et al., “Functional consequences of integrin-linked kinase activation in podocyte damage,” Kidney International, vol. 67, no. 2, pp. 514–523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett, and S. Dedhar, “Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 19, pp. 11211–11216, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Novak, S. C. Hsu, C. Leung-Hagesteijn et al., “Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4374–4379, 1998. View at Publisher · View at Google Scholar
  42. J. P. Thiery, H. Acloque, R. Y. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009. View at Publisher · View at Google Scholar · View at Scopus